Cyclotherapy: opening a therapeutic window in cancer treatment
Ingeborg M.M. van Leeuwen1
1 Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Ingeborg M.M. van Leeuwen, email:
Keywords: Cyclotherapy, chemotherapy, p53, nutlin-3, tenovin-6, leptomycin B, actinomycin D
Received: May 18, 2012, Accepted: June 15, 2012, Published: June 16, 2012
Cyclotherapy is a promising endeavor to improve cancer treatment by tackling the dose-limiting side effects of chemotherapy, especially for cancers harboring mutations in the TP53 tumor suppressor. In this particular context, pre-treatment with a p53 activator halts proliferation in healthy tissue, while leaving the p53-deficient tumor susceptible to conventional chemotherapy.
Ingeborg M.M. van Leeuwen
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Impact Journals LLC 2008